Short answer
Natera Inc (NTRA) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Q2 2026 results for quarter ended June 30, 2026 announced on August 6, 2026.
Natera Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026 announced on August 6, 2026
- Investor presentation accompanying earnings release, providing additional operating and financial context
- Detailed results and outlook contained in Exhibits 99.1 and 99.2
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $752.8M, up 37.7% YoY, driven by higher testing volume and average selling prices
- Tests processed 1,043,900, up 22.4%, with oncology tests up 57.2% to 296,700
- Gross margin 64.5% versus 63.4%, though $52.3M revenue accrual estimate change materially supported reported results
- Net loss narrowed to $67.0M, or $0.47 per share, from $100.9M, despite operating expenses rising 21.5%
- 2026 revenue guidance raised $100M at midpoint to $2.85B-$2.91B, with positive cash flow expected
Item EX-99.2 · Exhibit EX-99.2
- Q2 2026 revenue $752.8M, up ~38% year over year, with total tests exceeding 1.04M
- Clinical MRD oncology volume ~283K, up >56% year over year and ~34K sequentially, supporting Signatera growth
- Gross margin 64.5% versus 63.4%, while R&D increased to $228.1M to fund oncology and early-detection programs
- 2026 revenue guidance raised to $2.85B-$2.91B from $2.74B-$2.82B, with positive cash flow maintained
- Prospera Medicare surveillance coverage expanded, while Signatera achieved FDA, PMDA and EU IVDR milestones in 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Natera Inc 8-K filings
Get the next NTRA 8-K as it lands
Follow NTRA for push alerts, or ask the research agent what this filing means.